Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 2:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 243 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: n-Acetylcysteine Clear all
Recruiting Phase 2Phase 3 Interventional

Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Trial

NCT05664789
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
N acetyl cysteine, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
3 Years to 12 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 2, 2026, 2:28 AM EDT
Terminated Phase 1 Interventional

Safety and Efficacy of Anti-Oxidants and Anti-inflammatory Agents in Glaucoma and Diabetic Retinopathy

NCT02984813
View directory record Official record
Conditions
Open-angle Glaucoma, Diabetic Retinopathy
Interventions
GlaucoHealth, GlaucoSelect, Placebo
Drug
Lead sponsor
The New York Eye & Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 17, 2021 · Synced Oct 2, 2026, 2:28 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Role of Acetylcysteine in Creatinine Clearance

NCT00396396
View directory record Official record
Conditions
Creatinine Clearance
Interventions
Acetylcysteine
Drug
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
18 Years to 79 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 6, 2006 · Synced Oct 2, 2026, 2:28 AM EDT
Suspended Not applicable Interventional Accepts healthy volunteers

Insulin Resistance Study

NCT00614757
View directory record Official record
Conditions
Insulin Resistance, Metabolic Syndrome x
Interventions
N-acetylcysteine 20% 4ml, N-acetylcysteine 20% in 4 ml
Drug
Lead sponsor
Midwest Biomedical Research
Other
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2013
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 26, 2012 · Synced Oct 2, 2026, 2:28 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Effect of Sublingually Generated S-nitroso-N-acetylcysteine on Systemic Blood Pressure.

NCT05798481
View directory record Official record
Conditions
Hypertension, Cardiovascular Diseases
Interventions
Mixture of Sodium Nitrite and N-acetylcysteine (NAC) crytals.
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
21 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 2, 2026, 2:28 AM EDT
Active, not recruiting Phase 4 Interventional

The Effects of Positive Airway Pressure on the Mucolytic Effects of NAC (TEAM)

NCT06152653
View directory record Official record
Conditions
Asthma, COPD
Interventions
n-acetylcystine (NAC)+ albuterol, AeroEclipse-VersaPAP System
Drug · Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 2, 2026, 2:28 AM EDT
Completed Phase 3 Interventional Results available

Prevention of Serious Adverse Events Following Angiography

NCT01467466
View directory record Official record
Conditions
Acute Renal Failure, Kidney Disease, Coronary Artery Disease
Interventions
IV isotonic saline, IV isotonic bicarbonate, N-acetylcysteine, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
5,177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
35
States / cities
Tucson, Arizona • Little Rock, Arkansas • Palo Alto, California + 32 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Oct 2, 2026, 2:28 AM EDT
Completed Not applicable Interventional Results available

Physiological Effects of Nutritional Support in Patients With Parkinson's Disease

NCT02445651
View directory record Official record
Conditions
Parkinson Disease, Idiopathic Parkinson Disease
Interventions
Intravenous and Oral n-acetyl cysteine, Control group, Oral Supplements: Baicalin, Ganoderma, Omega 3 and Curcumin
Dietary Supplement · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
30 Years to 80 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 2, 2026, 2:28 AM EDT
Not listed Not applicable Interventional

Diabetic Retinopathy Functional Evaluation Study: Monitoring Carotenoid Vitamins Treatment Using ERG

NCT04117022
View directory record Official record
Conditions
Diabetes, Diabetic Retinopathy
Interventions
DVS supplementation
Dietary Supplement
Lead sponsor
ZeaVision, LLC
Industry
Eligibility
21 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Pomona, California • Tahlequah, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 23, 2021 · Synced Oct 2, 2026, 2:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

The Effects of a Glutathione Precursor (FT061452),on Serum and Intracellular Glutathione Levels

NCT01251315
View directory record Official record
Conditions
Oxidative Stress
Interventions
Placebo low dose, N Acetyl cysteine, 600mg (low dose), Proimmune 200 (FT061452) 3000mg low dose, Placebo (high dose), N Acetyl cysteine, 1200mg (high dose), FT061452, 6000mg high dose
Drug
Lead sponsor
Charles Drew University of Medicine and Science
Other
Eligibility
30 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 14, 2014 · Synced Oct 2, 2026, 2:28 AM EDT
Completed Phase 2 Interventional Results available

NAC for Treating Comorbid PTSD and SUD

NCT02911285
View directory record Official record
Conditions
Posttraumatic Stress Disorder (PTSD), Alcohol Use Disorder (AUD), Substance Use Disorder (SUD)
Interventions
N-acetylcysteine, Placebo, Cognitive behavioral therapy
Drug · Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Oct 2, 2026, 2:28 AM EDT
Completed Phase 2 Interventional Results available

N-acetylcysteine (NAC) for Children With Tourette Syndrome

NCT01172288
View directory record Official record
Conditions
Tourettes Syndrome, Tic
Interventions
N-Acetylcysteine (NAC), Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
8 Years to 17 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 10, 2017 · Synced Oct 2, 2026, 2:28 AM EDT
Terminated Phase 4 Interventional Results available

Clinical Trial of NAC in Asthma

NCT02605824
View directory record Official record
Conditions
Asthma
Interventions
n-acetylcystine, 0.9% saline
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Oct 2, 2026, 2:28 AM EDT
Completed Phase 2 Interventional Results available

Imaging GABAergic/Glutamatergic Drugs in Bipolar Alcoholics Alcoholics

NCT03220776
View directory record Official record
Conditions
Alcohol Use Disorder, Bipolar Disorder
Interventions
N-Acetylcysteine, Gabapentin, Placebo Oral Tablet
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Oct 2, 2026, 2:28 AM EDT
Completed Phase 1 Interventional

Study of the Safety and Tolerability of ALTH12 Versus Mesalamine Enema in Subjects With Left-Sided Ulcerative Colitis

NCT01020708
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
mesalamine, ALTH12-1:4, ALTH12-2:4
Drug
Lead sponsor
Altheus Therapeutics, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 29, 2011 · Synced Oct 2, 2026, 2:28 AM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers

N-Acetyl Cysteine Protects Pulpal Stem Cells in Endodontic Revascularization

NCT03451435
View directory record Official record
Conditions
Endodontic Disease
Interventions
N acetyl cysteine
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
6 Years to 18 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 2, 2026, 2:28 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Neurocircuit Strategy to Decrease Cocaine Cue Reactivity

NCT04155632
View directory record Official record
Conditions
Cocaine-Related Disorders
Interventions
N-acetylcysteine, Theta-burst stimulation (TBS)
Drug · Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Oct 2, 2026, 2:28 AM EDT
Enrolling by invitation Not applicable Interventional

PET-MRI in Chronic Traumatic Brain Injury (CTBI)

NCT03241732
View directory record Official record
Conditions
Chronic Traumatic Brain Injury
Interventions
Anti-inflammatory Diet, N-acetyl Cysteine, Neuro Emotive Technique
Other · Dietary Supplement · Behavioral
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Villanova, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Oct 2, 2026, 2:28 AM EDT
Completed Phase 1 Interventional

Role of HIV on Glutathione Synthesis and Oxidative Stress

NCT01355198
View directory record Official record
Conditions
HIV Infection, Erythrocyte Glutathione Deficiency
Interventions
Cysteine (as n-acetylcysteine) and glycine, Cysteine/glycine
Dietary Supplement
Lead sponsor
Baylor College of Medicine
Other
Eligibility
21 Years to 70 Years · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 7, 2013 · Synced Oct 2, 2026, 2:28 AM EDT
Terminated Not applicable Interventional

Vision Preservation and Restoration Following a 6 Month Trial of GlaucoCetin

NCT04784234
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
GlaucoCetin, Placebo
Dietary Supplement · Other
Lead sponsor
Wills Eye
Other
Eligibility
40 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 2, 2026, 2:28 AM EDT
Completed Early Phase 1 Interventional

A Pilot Study of N-acetylcysteine in Thrombotic Thrombocytopenia Purpura

NCT01808521
View directory record Official record
Conditions
Purpura, Thrombotic Thrombocytopenic, TTP
Interventions
N-Acetylcysteine
Drug
Lead sponsor
Bloodworks
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 20, 2017 · Synced Oct 2, 2026, 2:28 AM EDT
Not listed Phase 2 Interventional

Study of the Safety and Efficacy of Zoenasa® Versus Mesalamine Enema in Subjects With Left-Sided Ulcerative Colitis

NCT01586533
View directory record Official record
Conditions
Ulcerative Colitis, Left-sided Ulcerative Colitis, Distal Ulcerative Colitis
Interventions
Zoenasa-1:4, Mesalamine Enema
Drug
Lead sponsor
Altheus Therapeutics, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
45
States / cities
Birmingham, Alabama • Dothan, Alabama • Lakewood, Colorado + 39 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2014 · Synced Oct 2, 2026, 2:28 AM EDT
Completed Phase 2 Interventional Results available

Evaluating the Effect of Mucinex 1200mg on Mucociliary and Cough Clearance During an Acute Respiratory Infection

NCT01114581
View directory record Official record
Conditions
Acute Respiratory Infection
Interventions
Mucinex, Placebo
Drug
Lead sponsor
Reckitt Benckiser LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 19, 2018 · Synced Oct 2, 2026, 2:28 AM EDT
Withdrawn Phase 4 Interventional

A Pilot Study Investigating the Efficacy of Minocycline and N-Acetyl Cysteine for Bipolar Depression

NCT02719392
View directory record Official record
Conditions
Bipolar Disorder, Bipolar Depression
Interventions
N-acetylcysteine, Minocycline, Placebo
Dietary Supplement · Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 2, 2026, 2:28 AM EDT